Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Risk-Based Monitoring: US FDA Clarity And Industry Standards Aren't Enough
Jul 31 2019
•
By
Sue Sutter
Like the basic recipe for ice cream, risk-based monitoring may need some general standards that can be adapted by different sponsors and CROs. • Source: Shutterstock
More from Clinical Trials
More from R&D